Peripheral blood stem cell transplantation in young children: Experience with harvesting, mobilization and engraftment

Morris Kletzel*, Ron Longino, Alfred W Rademaker, Karina E. Danner-Koptik, Marie Olszewski, Elaine R Morgan

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this study was to determine the feasibility and assess optimal timing of harvesting peripheral blood stem cells (PBSC) for transplantation in young children. Thirteen children with body weight less than 25 kg, mean age of 3.9 years (1-9 yrs) who had recurrent solid tumors and leukemia were given tumor specific chemotherapy followed by IV rhG-CSF (5 μg/kg/d) for stem cell mobilization. Cytaphereses were done through a central venous line (CVL) during the marrow recovery phase (WBC >0.5 × 109/1). The phereses were analyzed separately and assigned to three groups depending on the WBC at the time of the pheresis: Group I (WBC <1.0 × 109/1), Group II [WBC in the range 1.0-3.0 × 109/1] and Group III (WBC > 3.0 × 109/1). Samples from each harvest were assayed for cell count, CFU-GM, BFU-E, CD34+ cell count, and tumor cell immunocytology in patients with neuroblastoma (NBL). A median of 3.2 × 108 mononuclear cells per kg (MNC/kg). [mean 2.8 × 108 MNC/kg, standard error of the mean (SEM) ± 0.74 (1.1-4.7)] were infused following myeloablative therapy. 78 phereses were performed in 13 children with a median weight of 18 kg (10-25 kg). A median of 5 phereses were performed per patient. There were no significant differences in the percentage and number of CD34+ cells, CFU-GM or BFU-E colonies assayed by plating 0.5 × 105 cells. Differences could be found in the total number of MNC (p<0.008) and the number of MNC/kg (p<0.001) between Groups II and III. No tumor cell contamination was detected in the NBL patients by immunocytology. All patients were rescued with PBSC and achieved sustained white cell engraftment (ANC>0.5 × 109/1) at a median of 13.5 d (10-25 d) and platelet engraftment (untransfused platelet count >20.0 × 109/1) at a median of 29 d (12-63 d). The only toxicity encountered during the phereses was thrombocytopenia in 4 patients whose median post-pheresis platelet count was 6.0 × 109/1 (3.0-9.01). It is concluded that collection of PBSC in young children is feasible and safe and can be performed through a cuffed CVL at the time of WBC recovery post mobilization with chemotherapy and G-CSF. Cytopheresis can be effectively performed when the peripheral WBC count approaches 1.0 × 109/1. Following stem cell infusion, engraftment was prompt and durable.

Original languageEnglish (US)
Pages (from-to)191-196
Number of pages6
JournalPediatric transplantation
Volume2
Issue number3
StatePublished - Aug 1 1998

Fingerprint

Peripheral Blood Stem Cell Transplantation
Blood Component Removal
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Cell Count
Platelet Count
Cytapheresis
Hematopoietic Stem Cell Mobilization
Drug Therapy
Neoplasms
Granulocyte Colony-Stimulating Factor
Neuroblastoma
Leukemia
Stem Cells
Blood Platelets
Bone Marrow
Body Weight
Weights and Measures

Keywords

  • Autologous transplant
  • Leukemia
  • PBSC
  • Solid tumors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

@article{c2e03f4b88d94f419ff54a6d8f6833c8,
title = "Peripheral blood stem cell transplantation in young children: Experience with harvesting, mobilization and engraftment",
abstract = "The purpose of this study was to determine the feasibility and assess optimal timing of harvesting peripheral blood stem cells (PBSC) for transplantation in young children. Thirteen children with body weight less than 25 kg, mean age of 3.9 years (1-9 yrs) who had recurrent solid tumors and leukemia were given tumor specific chemotherapy followed by IV rhG-CSF (5 μg/kg/d) for stem cell mobilization. Cytaphereses were done through a central venous line (CVL) during the marrow recovery phase (WBC >0.5 × 109/1). The phereses were analyzed separately and assigned to three groups depending on the WBC at the time of the pheresis: Group I (WBC <1.0 × 109/1), Group II [WBC in the range 1.0-3.0 × 109/1] and Group III (WBC > 3.0 × 109/1). Samples from each harvest were assayed for cell count, CFU-GM, BFU-E, CD34+ cell count, and tumor cell immunocytology in patients with neuroblastoma (NBL). A median of 3.2 × 108 mononuclear cells per kg (MNC/kg). [mean 2.8 × 108 MNC/kg, standard error of the mean (SEM) ± 0.74 (1.1-4.7)] were infused following myeloablative therapy. 78 phereses were performed in 13 children with a median weight of 18 kg (10-25 kg). A median of 5 phereses were performed per patient. There were no significant differences in the percentage and number of CD34+ cells, CFU-GM or BFU-E colonies assayed by plating 0.5 × 105 cells. Differences could be found in the total number of MNC (p<0.008) and the number of MNC/kg (p<0.001) between Groups II and III. No tumor cell contamination was detected in the NBL patients by immunocytology. All patients were rescued with PBSC and achieved sustained white cell engraftment (ANC>0.5 × 109/1) at a median of 13.5 d (10-25 d) and platelet engraftment (untransfused platelet count >20.0 × 109/1) at a median of 29 d (12-63 d). The only toxicity encountered during the phereses was thrombocytopenia in 4 patients whose median post-pheresis platelet count was 6.0 × 109/1 (3.0-9.01). It is concluded that collection of PBSC in young children is feasible and safe and can be performed through a cuffed CVL at the time of WBC recovery post mobilization with chemotherapy and G-CSF. Cytopheresis can be effectively performed when the peripheral WBC count approaches 1.0 × 109/1. Following stem cell infusion, engraftment was prompt and durable.",
keywords = "Autologous transplant, Leukemia, PBSC, Solid tumors",
author = "Morris Kletzel and Ron Longino and Rademaker, {Alfred W} and Danner-Koptik, {Karina E.} and Marie Olszewski and Morgan, {Elaine R}",
year = "1998",
month = "8",
day = "1",
language = "English (US)",
volume = "2",
pages = "191--196",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "3",

}

Peripheral blood stem cell transplantation in young children : Experience with harvesting, mobilization and engraftment. / Kletzel, Morris; Longino, Ron; Rademaker, Alfred W; Danner-Koptik, Karina E.; Olszewski, Marie; Morgan, Elaine R.

In: Pediatric transplantation, Vol. 2, No. 3, 01.08.1998, p. 191-196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peripheral blood stem cell transplantation in young children

T2 - Experience with harvesting, mobilization and engraftment

AU - Kletzel, Morris

AU - Longino, Ron

AU - Rademaker, Alfred W

AU - Danner-Koptik, Karina E.

AU - Olszewski, Marie

AU - Morgan, Elaine R

PY - 1998/8/1

Y1 - 1998/8/1

N2 - The purpose of this study was to determine the feasibility and assess optimal timing of harvesting peripheral blood stem cells (PBSC) for transplantation in young children. Thirteen children with body weight less than 25 kg, mean age of 3.9 years (1-9 yrs) who had recurrent solid tumors and leukemia were given tumor specific chemotherapy followed by IV rhG-CSF (5 μg/kg/d) for stem cell mobilization. Cytaphereses were done through a central venous line (CVL) during the marrow recovery phase (WBC >0.5 × 109/1). The phereses were analyzed separately and assigned to three groups depending on the WBC at the time of the pheresis: Group I (WBC <1.0 × 109/1), Group II [WBC in the range 1.0-3.0 × 109/1] and Group III (WBC > 3.0 × 109/1). Samples from each harvest were assayed for cell count, CFU-GM, BFU-E, CD34+ cell count, and tumor cell immunocytology in patients with neuroblastoma (NBL). A median of 3.2 × 108 mononuclear cells per kg (MNC/kg). [mean 2.8 × 108 MNC/kg, standard error of the mean (SEM) ± 0.74 (1.1-4.7)] were infused following myeloablative therapy. 78 phereses were performed in 13 children with a median weight of 18 kg (10-25 kg). A median of 5 phereses were performed per patient. There were no significant differences in the percentage and number of CD34+ cells, CFU-GM or BFU-E colonies assayed by plating 0.5 × 105 cells. Differences could be found in the total number of MNC (p<0.008) and the number of MNC/kg (p<0.001) between Groups II and III. No tumor cell contamination was detected in the NBL patients by immunocytology. All patients were rescued with PBSC and achieved sustained white cell engraftment (ANC>0.5 × 109/1) at a median of 13.5 d (10-25 d) and platelet engraftment (untransfused platelet count >20.0 × 109/1) at a median of 29 d (12-63 d). The only toxicity encountered during the phereses was thrombocytopenia in 4 patients whose median post-pheresis platelet count was 6.0 × 109/1 (3.0-9.01). It is concluded that collection of PBSC in young children is feasible and safe and can be performed through a cuffed CVL at the time of WBC recovery post mobilization with chemotherapy and G-CSF. Cytopheresis can be effectively performed when the peripheral WBC count approaches 1.0 × 109/1. Following stem cell infusion, engraftment was prompt and durable.

AB - The purpose of this study was to determine the feasibility and assess optimal timing of harvesting peripheral blood stem cells (PBSC) for transplantation in young children. Thirteen children with body weight less than 25 kg, mean age of 3.9 years (1-9 yrs) who had recurrent solid tumors and leukemia were given tumor specific chemotherapy followed by IV rhG-CSF (5 μg/kg/d) for stem cell mobilization. Cytaphereses were done through a central venous line (CVL) during the marrow recovery phase (WBC >0.5 × 109/1). The phereses were analyzed separately and assigned to three groups depending on the WBC at the time of the pheresis: Group I (WBC <1.0 × 109/1), Group II [WBC in the range 1.0-3.0 × 109/1] and Group III (WBC > 3.0 × 109/1). Samples from each harvest were assayed for cell count, CFU-GM, BFU-E, CD34+ cell count, and tumor cell immunocytology in patients with neuroblastoma (NBL). A median of 3.2 × 108 mononuclear cells per kg (MNC/kg). [mean 2.8 × 108 MNC/kg, standard error of the mean (SEM) ± 0.74 (1.1-4.7)] were infused following myeloablative therapy. 78 phereses were performed in 13 children with a median weight of 18 kg (10-25 kg). A median of 5 phereses were performed per patient. There were no significant differences in the percentage and number of CD34+ cells, CFU-GM or BFU-E colonies assayed by plating 0.5 × 105 cells. Differences could be found in the total number of MNC (p<0.008) and the number of MNC/kg (p<0.001) between Groups II and III. No tumor cell contamination was detected in the NBL patients by immunocytology. All patients were rescued with PBSC and achieved sustained white cell engraftment (ANC>0.5 × 109/1) at a median of 13.5 d (10-25 d) and platelet engraftment (untransfused platelet count >20.0 × 109/1) at a median of 29 d (12-63 d). The only toxicity encountered during the phereses was thrombocytopenia in 4 patients whose median post-pheresis platelet count was 6.0 × 109/1 (3.0-9.01). It is concluded that collection of PBSC in young children is feasible and safe and can be performed through a cuffed CVL at the time of WBC recovery post mobilization with chemotherapy and G-CSF. Cytopheresis can be effectively performed when the peripheral WBC count approaches 1.0 × 109/1. Following stem cell infusion, engraftment was prompt and durable.

KW - Autologous transplant

KW - Leukemia

KW - PBSC

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=0032129802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032129802&partnerID=8YFLogxK

M3 - Article

C2 - 10084741

AN - SCOPUS:0032129802

VL - 2

SP - 191

EP - 196

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 3

ER -